REDWOOD CITY, Calif., May 30, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced a schedule of sessions and posters highlighting the company’s Lumivascular technology at the New Cardiovascular Horizons (NCVH) annual conference taking place this week in New Orleans, Louisiana, from Tuesday, May 29, through Friday, June 1, 2018.
Avinger Lumivascular technology highlights include the following sessions (all times Central Daylight Time):
- Dr. Patrick Muck intends to present on Pantheris optical coherence tomography guided atherectomy results in Crescent City Ballroom; Thursday, May 31, 3:28 p.m.
- Dr. Ian Cawich intends to present on optical coherence tomography guided interventions in Crescent City Ballroom; Thursday, May 31, 3:52 p.m.
- Dr. Arne Schwindt submitted a poster on his case experiences in Germany with the next-generation Pantheris, recently cleared by the FDA for commercialization in the United States.
- Dr. Glen Schwartzberg has submitted a poster of a case series for a novel use of Pantheris image-guided atherectomy for revascularization in certain applications.
About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD). Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the PantherisÒ family of atherectomy devices. Avinger is based in Redwood City, CA. For more information, please visit www.avinger.com.
Public Relations Contact:
VP of Marketing & Business Operations
Chief Business Officer & CFO